Company Encyclopedia
View More
name
Xtant Med
XTNT.US
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. The company offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, which can be compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications.
330.79 B
XTNT.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Health Care SuppliesIndustry
Industry Ranking6/42
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE3.64%C
    • Profit Margin1.32%C
    • Gross Margin66.13%A
  • Growth ScoreB
    • Revenue YoY16.88%B
    • Net Profit YoY109.96%A
    • Total Assets YoY7.52%B
    • Net Assets YoY10.19%B
  • Cash ScoreA
    • Cash Flow Margin7600.40%A
    • OCF YoY16.88%B
  • Operating ScoreA
    • Turnover1.3A
  • Debt ScoreC
    • Gearing Ratio52.61%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Companion Spine LLC Completes Acquisition of the Business and Assets of Paradigm Spine GmbH, including the Coflex® and CoFix® Spine Implants and All Other Implant Systems, from Xtant™ Medical Holdings, Inc. | XTNT Stock News

    Companion Spine LLC has completed the acquisition of Paradigm Spine GmbH from Xtant Medical Holdings, Inc. This acquisition creates the largest portfolio of minimally invasive surgical solutions for spine stabilization. The combined company will treat lumbar spinal stenosis and degenerative disc disease globally. Anthony G. Viscogliosi will lead the company, focusing on expanding spine care solutions. Paradigm Spine retains its name and office in Germany, enhancing global growth and partnerships.

    StockTitan·
    US
    XTNT
    +2.09%
    StockTitan·
    US
    XTNT
    +2.09%

    Xtant Med | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 33.26 M

    LB filings·
    US
    XTNT
    +2.09%
    LB filings·
    US
    XTNT
    +2.09%

    Xtant Med | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 33.26 B

    LB filings·
    US
    XTNT
    +2.09%
    LB filings·
    US
    XTNT
    +2.09%

    Xtant Medical Hldgs (AMEX: XTNT) to report EPS of $-0.02 on 2025-11-11. Investors hopeful for positive guidance.

    Xtant Medical Holdings (AMEX: XTNT) is set to reveal its quarterly earnings on Tuesday, November 11, 2025. Analysts predict an earnings per share (EPS) of -$0.02 for Xtant Medical Holdings. This announcement is highly anticipated, as investors hope for results that exceed expectations and positive guidance for the following quarter. Stay updated for more details on the upcoming release.

    Unusual Whales·
    US
    XTNT
    +2.09%
    Unusual Whales·
    US
    XTNT
    +2.09%

    Xtant Medical Approves Equity Plan Amendment at Meeting

    Xtant Medical Holdings approved an amendment to its 2023 Equity Incentive Plan at its annual stockholders meeting on November 7, 2025, increasing shares by 12,300,000. The meeting also included the election of directors and the ratification of Grant Thornton LLP as the accounting firm. Analyst ratings for XTNT stock are currently a Hold with a $1.00 price target, reflecting strong revenue growth but challenges in financial performance. The company specializes in regenerative medicine products, particularly in orthopedics and spine.

    Tip Ranks·
    US
    XTNT
    +2.09%
    Tip Ranks·
    US
    XTNT
    +2.09%
    © 2025 Longbridge｜Disclaimer